Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 11, 2025 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 11, 2025 · Filed March 19, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,065 |
Reported balance
After 2025-06-11 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 6,163 · Balance 31,065 F1: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 11,279 | $0.00 Strike: $24.34 | $0.00 |
DisclosureSEC source: 0001396814-25-000087 · wk-form4_1749845910.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 9,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000087 · wk-form4_1749845910.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,901 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 11, 2025 Filed Mar 19, 2026 21:43 UTC Amendment | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019892 · wk-form4a_1773956593.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,065 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,179 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001396814-24-000072 · wk-form4_1718316735.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000072 · wk-form4_1718316735.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,902 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,925 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038024 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,925 Underlying: Common Stock · 12,925 shares Expires 2033-06-14 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038024 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,672 F1 · shares: Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $29.90 | $0.00 |
DisclosureSEC source: 0001209191-23-036270 · doc4.xml · derivative · entry 3 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · derivative.exercise_date: The option shares vested in 24 equal successive monthly installments over the 24-month period following the date of grant, subject to the reporting person's continued service as a director. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 15,000 | $37.04 | $555,600.00 |
DisclosureSEC source: 0001209191-23-036270 · doc4.xml · nonDerivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,897 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.72 to $37.43, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 15,000 | $29.90 | $448,500.00 |
DisclosureSEC source: 0001209191-23-036270 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:29 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,225 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035224 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,225 Underlying: Common Stock · 8,225 shares Expires 2032-06-08 Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:29 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035224 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,897 F1 · shares: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 7,626 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040085 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2031-06-09 Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040085 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,737 F1 · shares: Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:26 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,027 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036041 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027 Underlying: Common Stock · 8,027 shares Expires 2030-06-09 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:26 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036041 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,671 F1 · shares: Represents restricted stock units that vest on June 3, 2021, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,437 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035092 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Stock · 8,437 shares Expires 2029-06-05 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035092 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,411 F1 · shares: Represents restricted stock units that vest on June 3, 2020, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 1,000 | $39.14 | $39,140.00 |
DisclosureSEC source: 0001209191-19-018092 · doc4.xml · nonDerivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,277 Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 700 | $38.72 | $27,104.00 |
DisclosureSEC source: 0001209191-19-018092 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,277 Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 20:34 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 1,000 | $44.61 | $44,611.20 |
DisclosureSEC source: 0001209191-18-048951 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 4,693 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038195 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Underlying: Common Stock · 4,693 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038195 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,577 F1 · shares: Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 01:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 1,000 | $41.60 | $41,602.50 |
DisclosureSEC source: 0001209191-17-060479 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,795 Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 2,714 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040691 · doc4.xml · derivative · entry 2 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,714 Underlying: Common Stock · 2,714 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040691 · doc4.xml · nonDerivative · entry 1 Kronenfeld Mark A. · CIK 0001578074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,795 F1 · shares: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.